N🟁N

ROCHESTER, N.Y.--([ BUSINESS WIRE ])--Lucid, Inc. (OTCBB: LCDX, LCDXW) today announced that the units sold (OTCBB: LCDCU) in the previously announced underwritten public offering have been separated according to the provisions in Lucidas Prospectus dated December 27, 2011. As of February 27, 2012 Lucidas common stock and warrants were listed on the Over the Counter Bulletin Board under the ticker symbols LCDX (OTCBB: LCDX) and (OTCBB: LCDXW), respectively.

About Lucid, Inc.

Lucid, Inc. is a leader in noninvasive skin cancer imaging and diagnosis through the use of its FDA cleared VivaScope confocal imagers and its innovative VivaNet telepathology system that allows secure, HIPAA compliant, near real-time collaboration between dermatologists and pathologists. VivaNet provides rapid online medical image transfer storage and retrieval, enabling critical collaborative consultations at the point and time of care. Lucidas VivaScopes provide images that can assist physicians in forming medical decisions in cases of melanoma and other skin cancers.

VivaScope and VivaNet are registered trademarks of Lucid, Inc.

Safe Harbor

This press release contains aforward looking statementsa within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as aexpects,a acontemplates,a aanticipates,a aplans,a aintends,a abelieves,a aassumesa and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the risk factors section of the prospectus.